EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer

Chayanee Samdaengpan iD, Prakongboon Sungkasubun, Worawit Chaiwiriyawong, Archara Supavavej iD, Jomtana Siripaibun, Chumut Phanthunane iD, Walaipan Tantiyavarong iD, Wisut Lamlertthon, Teerapat Ungtrakul iD, Kriangkrai Tawinprai iD, Kamonwan Soonklang iD, Thitapha Thongchai iD und 1 weitere

JCO Global Oncology · 2024

DOI: 10.1200/go.23.00458 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Chayanee Samdaengpan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand. Hauptthemen laut MEDLINE: Neoplasms, COVID-19, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Corticosteroids are known to diminish immune response ability, which is generally used in routine premedication for chemotherapy. The intersecting of timeframe between the corticosteroid's duration of action and peak COVID-19 vaccine efficacy could impair vaccine immunogenicity. Thus, inquiring about corticosteroids affecting the efficacy of vaccines to promote effective immunity in this population is needed. METHODS This was a prospective longitudinal observational cohort study that enrolled patients with solid cancer classified into dexamethasone- and nondexamethasone-receiving groups. All participants were immunized with two doses of ChAdOx1 nCoV-19 or CoronaVac vaccines. This study's purpose was to compare corticosteroid's effect on immunogenicity responses to the SARS-CoV-2 S protein in patients with cancer after two doses of COVID-19 vaccine in the dexamethasone and nondexamethasone group. Secondary outcomes included the postimmunization anti–spike (S) immunoglobin G (IgG) seroconversion rate, the association of corticosteroid dosage, time duration, and immunogenicity level. RESULTS Among the 161 enrolled patients with solid cancer, 71 and 90 were in the dexamethasone and nondexamethasone groups, respectively. The median anti–S IgG titer after COVID-19 vaccination in the dexamethasone group was lower than that in the nondexamethasone group with a statistically significant difference (47.22 v 141.09 U/mL, P = .035). The anti–S IgG seroconversion rate was also significantly lower in the dexamethasone group than in the nondexamethasone group (93.83% v 80.95%, P = .023). The lowest median anti–SARS-CoV-2 IgG titer level at 7.89 AU/mL was observed in patients with the highest dose of steroid group (≥37 mg of dexamethasone cumulative dose throughout the course of chemotherapy [per course]) and patients who were injected with COVID-19 vaccines on the same day of receiving dexamethasone, 25.41 AU/mL. CONCLUSION Patients with solid cancer vaccinated against COVID-19 disease while receiving dexamethasone had lower immunogenicity responses than those who got vaccines without dexamethasone. The direct association between the immunogenicity level and steroid dosage, as well as length of duration from vaccination to dexamethasone, was observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCOVID-19COVID-19 VaccinesSARS-CoV-2DexamethasoneImmunogenicity, VaccineHumansMaleFemaleMiddle AgedProspective StudiesAgedLongitudinal StudiesAntibodies, ViralAdrenal Cortex HormonesAdultImmunoglobulin GChAdOx1 nCoV-19Spike Glycoprotein, Coronavirus

Substanzen

COVID-19 VaccinesDexamethasoneAntibodies, ViralAdrenal Cortex HormonesImmunoglobulin GChAdOx1 nCoV-19Spike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Division of Medical Oncology, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.
  • Faculty of Medicine and Public Health, Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.
  • Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.
  • Chulabhorn Learning and Research Center, Chulabhorn Royal Academy, Bangkok, Thailand.

ORCID-Profile: Chayanee Samdaengpan, Archara Supavavej, Chumut Phanthunane, Walaipan Tantiyavarong, Teerapat Ungtrakul, Kriangkrai Tawinprai, Kamonwan Soonklang, Thitapha Thongchai, Piyarat Limpawittayakul

Zitieren

APA

Samdaengpan, C., Sungkasubun, P., Chaiwiriyawong, W., Supavavej, A., Siripaibun, J., Phanthunane, C., Tantiyavarong, W., Lamlertthon, W., Ungtrakul, T., Tawinprai, K., Soonklang, K., Thongchai, T., & Limpawittayakul, P. (2024). Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer. JCO Global Oncology. https://doi.org/10.1200/go.23.00458

Vancouver

Samdaengpan C, Sungkasubun P, Chaiwiriyawong W, Supavavej A, Siripaibun J, Phanthunane C, et al. Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer. JCO Global Oncology. 2024. doi:10.1200/go.23.00458

BibTeX
@article{Samdaengpan2024,
  author = {Samdaengpan, Chayanee and Sungkasubun, Prakongboon and Chaiwiriyawong, Worawit and Supavavej, Archara and Siripaibun, Jomtana and Phanthunane, Chumut and Tantiyavarong, Walaipan and Lamlertthon, Wisut and Ungtrakul, Teerapat and Tawinprai, Kriangkrai and Soonklang, Kamonwan and Thongchai, Thitapha and Limpawittayakul, Piyarat},
  title = {Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.23.00458}
}
Kostenlos starten →